"Designing Growth Strategies is in our DNA"

Human Immunodeficiency Virus (HIV) Treatment Market Size, Share and Global Trend By Drug Class (Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), Protease Inhibitors (PIs), Integrase Inhibitor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) and Geography Forecast till 2026

Region : Global | Published Date: Ongoing | Report ID: FBI101245| Status : Upcoming

 

KEY INDUSTRY INSIGHTS

Human Immunodeficiency Virus (HIV) disease is a major global health issue. Human Immunodeficiency Virus (HIV) is a virus that leads to condition known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency Virus (HIV) attacks the body’s immune system specifically the CD4 cells (T cells), which help the immune system to fight against infections.

Absence of these CD4 cells, reders the body’s immune system inefficient to fight against chronic and acute diseases. Currently avialable treatment options are inefficient to completely cure the disease. Antiretroviral therapy (ART) is used as a treatment of Human Immunodeficiency Virus (HIV). Antiretroviral therapy (ART) slows down the progression of HIV in the body.

To get information on various segments, share your queries with us


There is an increasing effort being undertaken by regional and national governments, and non-profit organizations, to promote awareness regarding Human Immunodeficiency Virus (HIV) disease, and to eradicate the social stigma associated with the disease. This is aimed towards increasing diagnosis rate of Human Immunodeficiency Virus (HIV) among patients in emerging countries.

These initiatives are anticipated to present a comparatively larger pool of people undergoing diagnosis for HIV, and subsequently fuel the demand for Human Immunodeficiency Virus (HIV) drugs during the forecast period. This along with increasing prevalence of Human Immunodeficiency Virus (HIV) disease in emerging countries including China, India, and African countries, are factors projected to drive the growth of the global human immunodeficiency virus (HIV) treatment market during 2019-2026.


According to World Health Organization (WHO) in 2017 estimated 36.9 million people were infected with Human Immunodeficiency Virus (HIV) globally, however only 21.7 million people received treatment. Major factors attributed to this were lack of diagnosed HIV patients, high cost of Human Immunodeficiency Virus (HIV) drugs & social stigma. These are some major factors restraining the growth of human immunodeficiency virus (HIV) treatment market.


Key Players Covered


Some of the major companies that are present in the global human immunodeficiency virus (HIV) treatment market are Abbott, Pfizer Inc., Novartis AG, Sanofi, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Gilead Sciences, Inc., ViiV Healthcare and other players.


SEGMENTATION






















SEGMENTATION



 DETAILS



By Drug Class



· Non-nucleoside reverse transcriptase inhibitors (NNRTIs)


· Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)


· Protease Inhibitors (PIs)


· Integrase Inhibitor


· Others



By Distribution Channel



· Hospital Pharmacies


· Retail Pharmacies


· Others



By Geography



· North America (USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 


Key Insights



  • Pipeline Analysis, Key Players / Region

  • New Initiatives Undertaken by Government & Non-Government Organizations, Key Countries.

  • Pricing Analysis, Key Players, 2018

  • Key Mergers and Acquisitions.

  • Prevalence of Human Immunodeficiency Virus (HIV) Disease, Key Countries.


Regional Analysis


The global human immunodeficiency virus (HIV) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominates the global human immunodeficiency virus (HIV) treatment market in 2018. In U.S, the Centers for Disease Control and Prevention sponsored a campaign that motivated people to get tested for HIV. This campaign resulted in increased number of diagnosed HIV patients and subsequently increased demand for treatment in U.S. In Middle East & Africa, human immunodeficiency virus (HIV) treatment market is projected to grow at a comparatively higher CAGR during 2019-2026. This region contains a large population of HIV patients in comparison with other regions. Undiagnosed HIV patients and low per capita healthcare expenditure are the major reasons restraining the growth of the market in this region. However, government initiatives to provide low-cost treatment in this region, is expected to drive the growth of the market during 2019-2026.


Key Industry Developments






  • In 2018, researchers from Massachusetts Institute of Technology developed a capsule that was able to deliver a week worth of HIV drug in a single dose. This lead to increase in patient’s compliance for Antiretroviral Therapy.
  • First in human (FIH) clinical trial was held by Zion Medical in 2018, which found that the synthetic peptide drug (Gammora) reduced the level of viral RNA in patients’ blood up to 90% after five weeks. When given in combination with the approved HIV drugs: lopinavir and ritonavir, it reduced viral RNA levels up to 99% after five weeks.
  • In Aug 2018, Merck & Co., Inc. announced that FDA approved its two new antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of HIV-1, the most common strain of virus.
  • In 2018 FDA approved Biktarvy, a daily single dose HIV medication by Gilead Sciences. Biktarvy is specifically indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace current antiretroviral regimen.
  • In 2019, Food and Drug Administration finalized two guidlines on PrEP to support the manufacturers developing a new version of Antiretroviral medications.

Human Immunodeficiency Virus (HIV) Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

lpsos
Sedana-Cyan-Black-Tag
novo-nordisk
Bio-Rad
chong-kun-dang

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X